Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors
Jennifer A. Chan(Association for Jewish Studies), Matthew H. Kulke(Brigham and Women's Hospital), Rebecca A. Miksad(Brigham and Women's Hospital), Pankaj Bhargava(University of North Carolina at Chapel Hill), Hui Zheng(Association for Jewish Studies), Craig C. Earle(Canadian Partnership Against Cancer), Keith Stuart(Brigham and Women's Hospital), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), Peter C. Enzinger(Dana-Farber Cancer Institute), Charles S. Fuchs(Yale Cancer Center), Jeffrey A. Meyerhardt(CancerCare)
Cited by 301
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
|JAMA Oncology|2018|1.8k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k